Definium Therapeutics, Inc. (DFTX) stock
Close on Nov 11, 2026Market cap $4.63BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $4.63B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.78
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$337.48M
- EPS, diluted
- -$3.11
- Book value per share
- $7.05
- Diluted shares
- 137M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $34.64
- Open
- $35.23
- Day's range
- $33.91 – $35.23
- Volume
- 1,441,543
- Average volume (20 days)
- 1,728,008
- Index membership
- Russell 2000 (since Mar 2026), Russell 3000 (since Feb 2026)
- Beta (5 years)
- 1.76
- 52-week range
- $10.46 – $49.70
- RSI (14 days)
- 47.9
- Volatility (1 year)
- 77.8%
- Relative volume
- 0.70×
- WACC
- 13.6%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DFTX | S&P 500 | Difference | DFTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.6% | -2.4% | −4.2 pts | ||
| 3 months | -15.7% | -1.2% | −14.6 pts | ||
| Year to date | +157.4% | +12.3% | +145.1 pts | ||
| 1 year | +176.2% | +12.4% | +163.8 pts | ||
| 3 years | +1278.8% | +78.8% | +1200.0 pts | +139.8% | +21.4% |
| 5 years | +2.1% | +75.2% | −73.0 pts | +0.4% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Definium Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- News
- Update
- Update
About Definium Therapeutics
Medicinal Chemicals & Botanical Products
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for brain health disorders. The company's pipeline consists of pharmaceutically optimized product candidates derived from psychedelic and empathogen drug classes. Its lead product candidate, DT120 ODT, is an orally disintegrating tablet formulation of lysergide D-tartrate being evaluated for adult patients with generalized anxiety disorder and major depressive disorder. Its second lead candidate, DT402, is an optimized form of the R-enantiomer of MDMA under evaluation to address core symptoms in adult patients with autism spectrum disorder.
Company profile, executives and historyDefinium Therapeutics stock: common questions
What is Definium Therapeutics's stock price?
DFTX closed at $34.47 on Nov 11, 2026, down 0.49% on the day. Over the past 52 weeks it traded between $10.46 and $49.70.
What is Definium Therapeutics's market cap?
Definium Therapeutics was worth $4.63B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DFTX's P/E ratio?
Definium Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.11), so it has no meaningful P/E ratio.
Does Definium Therapeutics pay a dividend?
No. Definium Therapeutics has not paid a cash dividend over the last twelve months.
When does Definium Therapeutics report earnings next?
Definium Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has DFTX stock performed over the past year?
Including dividends, DFTX returned +176.2% over the past year, against +12.4% for the S&P 500.
How many DFTX shares are sold short?
10M shares were sold short at the latest FINRA report, 7.40% of the float, or 5.8 days of average trading volume.
Who are Definium Therapeutics's competitors?
Companies most similar to Definium Therapeutics by business, industry and size include RGC, RAPH, AIBT, IXHL, VTGN.
See a number that looks wrong?